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Posterior cortical atrophy
Sebastian J Crutch, Manja Lehmann, Jonathan M Schott, Gil D Rabinovici, Martin N Rossor, Nick C Fox
Posterior cortical atrophy (PCA) is a neurodegenerative syndrome that is characterised by progressive decline in 
visuospatial, visuoperceptual, literacy, and praxic skills. The progressive neurodegeneration aﬀ ecting parietal, 
occipital, and occipitotemporal cortices that underlies PCA is attributable to Alzheimer’s disease in most patients. 
However, alternative underlying causes, including dementia with Lewy bodies, corticobasal degeneration, and 
prion disease, have also been identiﬁ ed, and not all patients with PCA have atrophy on clinical imaging. This 
heterogeneity has led to inconsistencies in diagnosis and terminology and diﬃ  culties in comparing studies from 
diﬀ erent centres, and has restricted the generalisability of ﬁ ndings from clinical trials and investigations of 
factors that drive phenotypic variability. Important challenges remain, including the identiﬁ cation of factors 
associated not only with the selective vulnerability of posterior cortical regions but also with the young age of 
onset of PCA. Greater awareness of the syndrome and agreement over the correspondence between syndrome-
level and disease-level classiﬁ cations are needed to improve diagnostic accuracy, clinical management, and the 
design of research studies.
Introduction
Posterior cortical atrophy (PCA) is a neurodegenerative 
condition characterised by a progressive, often striking, 
and fairly selective decline in visual-processing skills 
and other functions that depend on parietal, occipital, 
and occipitotemporal regions of the brain. Age at onset 
of PCA is typically 50–65 years, and the syndrome is 
associated with various underlying pathological 
features. PCA has been recognised for more than two 
decades and yet, compared with other conditions, is 
relatively neglected by researchers. Patients often face 
considerable delays in diagnosis owing to the young 
age at onset and unusual symptoms at presentation. 
Furthermore, the term PCA has been applied 
in consistently, making comparison across studies 
diﬃ  cult to achieve. Although there have been moves to 
deﬁ ne neurodegenerative diseases by their underlying 
pathological features, such progress in relation to PCA 
is limited currently by scant speciﬁ city in available 
diagnostic criteria and an absence of clarity with respect 
to relations between PCA and related syndromic 
classiﬁ cations, such as aphasic, amnestic, and 
dysexecutive Alzheimer’s disease pheno types and 
corticobasal syndrome.
In this Review we outline the clinical, psychological, 
imaging, epidemiological, genetic, and pathological 
features of PCA. We argue that, within pathological 
subgroups, characterisation of atypical phenotypes 
such as PCA will enable identiﬁ cation of biological 
factors that promote or protect against pathological 
changes in speciﬁ c brain networks. Problems with and 
possible solutions to current diagnostic and 
terminological conundrums are considered, with 
particular reference to implications for future design 
of clinical and research trials that include people with 
PCA. We also aim to increase awareness and improve 
identiﬁ cation of early and unusual symptoms of PCA 
and to provide guidance on the provision of support, 
care, and education for patients, carers, and health-care 
professionals.
History and deﬁ nitions
The term PCA was ﬁ rst used to describe people with 
predominant deﬁ cits in higher-order visual processing, 
a subset of whom also presented with striking atrophy 
in parieto-occipital areas of the brain.1 The outlined 
syndrome accorded with other early reports of patients 
with similar clinical characteristics.2–9 Without histo-
pathological data, Benson and colleagues1 deemed the 
clinical presentation of PCA to be suﬃ  ciently distinct 
from that of Alzheimer’s or Pick’s disease “to warrant 
classing them separately until deﬁ nitive pathologic 
information becomes available”. Subsequent histopatho-
logical studies identiﬁ ed Alzheimer’s disease as the 
most common underlying pathological feature, leading 
to synonymous use of the terms PCA, biparietal 
Alzheimer’s disease, and visual variant of Alzheimer’s 
disease in some studies.10–14 The term progressive 
posterior cortical dysfunction has also been used to 
describe clinical symptoms in aﬀ ected individuals who 
do not have clear posterior atrophy.15 However, PCA is 
also associated with pathological features that are not 
linked to Alzheimer’s disease, which has led to calls for 
PCA to be regarded as a distinct nosological entity with 
its own diagnostic criteria.16,17
Epidemiology
The prevalence and incidence of PCA are currently 
unknown; obtaining these data will depend on the 
adoption of consistent diagnostic criteria. Furthermore, 
any value is likely to be an underestimate because of poor 
general awareness of the syndrome. However, Snowden 
and colleagues18 noted that, of 523 patients with 
Alzheimer’s disease presenting to one specialist centre 
for cognitive disorders, 24 (5%)  had a visual presentation 
(also labelled PCA) and a further 13 (3%) had an apraxic 
presentation.
Age at onset tends to be much earlier in patients with 
PCA than in those with typical amnestic Alzheimer’s 
disease, with most studies recording age of PCA symptom 
onset from mid-50s to early 60s,17,19 although some 
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researchers have reported a wider age spread 
(45–74 years,20 40–86 years).21 In terms of sex distribution, 
no diﬀ erence in prevalence has been noted on the basis 
of sex,15,17,19 whereas other groups have reported an over-
representation in women.18,20–24
Neuropsychological features
The neuropsychological deﬁ cits cited most frequently 
in individuals with PCA are visuospatial and visuo-
perceptual impairments, alexia, and features of Bálint’s 
syndrome (simultanagnosia, oculomotor apraxia, optic 
ataxia, environmental agnosia) and Gerstmann’s 
syn drome (acalculia, agraphia, ﬁ nger agnosia, left–right 
disorientation; ﬁ gure 1).15,17,19–21,25–31 Deﬁ cits in working 
memory and limb apraxia have also been noted.20 
Findings of longitudinal studies indicate that anterograde 
memory, executive functions, and linguistic skills, which 
are sometimes preserved strikingly in earlier stages of 
disease, gradually deteriorate in some patients with PCA 
as they progress to a more global dementia state.10,19,23
Although higher-order visual problems, such as 
diﬃ  culties with object and space perception, are reported 
more often than are basic visual impairments, many such 
problems are at least partly due to deﬁ cits in more basic 
visual processing—eg, form, motion, colour, and point 
localisation. In a detailed comparison of basic and higher-
order perception,32 all patients with PCA showed 
impairment in at least one basic visual process, 
emphasising the vulnerability of fundamental aspects of 
vision associated with occipital cortical dysfunction. This 
study also indicated speciﬁ c correlations of basic visual 
processing with higher-order visuospatial and visuo-
perceptual skills, but not with non-visual parietal functions 
(such as calculation and spelling), suggesting speciﬁ c 
involvement of visual networks in PCA.32
Basic and higher-order visual deﬁ cits, in combination, 
have predictable outcomes on the performance of 
PCA patients on general neuropsychological tests—
eg, performance IQ in patients is often up to 30–40 points 
lower than verbal IQ. Performance on cognitive tasks 
with any relevant visual component (eg, visual memory 
recall, trail-making test, Stroop test) is vulnerable to 
impairment and misinterpretation, and thus accurate 
assessment requires selection of tasks that minimise 
visual demands (eg, auditory-verbal memory tasks, 
naming from verbal description).
Many patients with PCA also have unusual symptoms, 
referred to as positive perceptual phenomena, which 
include abnormally prolonged colour after-images,33 
reverse size phenomena,34,35 perception of movement of 
static stimuli,35 and in one individual,35 180° upside-down 
reversal of vision. Reading skills can be limited by several 
processes, including visual disorientation (getting lost on 
the page), reverse size phenomena (accurately perceiving 
small but not large print), and visual crowding (impaired 
identiﬁ cation of constituent letters of a word owing to 
excessive integration of visual features from surrounding 
letters).36–38 PCA can also lead to primary peripheral 
dyslexias.39,40 Anecdotally, individuals with PCA frequently 
report heightened sensitivity to glare from shiny surfaces 
and can experience a range of localised sensation and 
pain phenomena and disturbances of balance and bodily 
orientation, which could potentially be linked to deranged 
visuovestibular interactions.
Should PCA be deemed a unitary clinicoanatomical 
syndrome or, rather, a collection of related but distinct 
syndromic subtypes? By extrapolation from basic 
neuroscientiﬁ c evidence of distinct cortical streams that 
process diﬀ erent types of visual information,41,42 
researchers have suggested that separate parietal (dorsal), 
occipitotemporal (ventral), and primary visual (striate 
cortex, caudal) forms of PCA exist.12,13 However, these 
claims are based on ﬁ ndings from individual case reports. 
Subsequent studies of neuropsychological case series 
have failed to provide evidence to support a pure ventral-
stream syndrome19 and, rather, have indicated 
considerable overlap in neuropsychological proﬁ les and 
patterns of cortical thinning in patients with behaviourally 
deﬁ ned predominantly dorsal-stream or ventral-stream 
Figure 1: Visual dysfunction in posterior cortical atrophy
Individuals with posterior cortical atrophy have diﬃ  culty identifying objects and 
faces, particularly when they consist of many parts or are viewed from an 
unfamiliar (non-canonical) perspective. Eye-tracking studies contrasting scene 
perception in healthy individuals (A) and people with posterior cortical atrophy 
(B) suggest that patients have poor top-down guidance and control of 
oculomotor function. Circles represent ﬁ xation locations and circle size 
represents ﬁ xation duration. Patients with posterior cortical atrophy ﬁ xate 
prominent features initially (eg, dome on pier), but subsequently ﬁ xate 
relatively uninformative aspects of the scene (eg, sea or sky) and miss important 
contextual details (eg, beachfront or near the end of the pier). Images from 
Tim Shakespeare and Sebastian Crutch (unpublished).
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impairments.32 Thus, these ﬁ ndings suggest that 
phenotypic diﬀ erences might most appropriately be 
judged to represent points on a continuum of variation 
within PCA.
Clinical features
Clinical presentation of PCA is aﬀ ected by several factors. 
These include time taken before an individual presents to 
medical services or is referred to a cognitive specialist; the 
speciﬁ c pattern of deﬁ cits; in some people, the underlying 
pathological features; and the patient’s psychological 
response to their symptoms. The relative rarity of PCA, 
the sometimes unusual nature of its symptoms, and the 
fairly young age at onset can lead to misdiagnosis of many 
patients as depressed, anxious, or even malingering in 
early stages of the disease. Early anxiety is (at least 
anecdotally) a common feature, perhaps indicating that 
patients with PCA typically have some insight into the 
possibility that they have a medical problem, even if its 
nature is unclear. Furthermore, even to experienced 
cognitive neurologists, a patient’s initial history can be 
more suggestive of anxiety, until examination shows 
impairment that relates to function of the parietal lobe, 
the occipital lobe, or both of these areas. Patients are 
usually referred ﬁ rst to opticians and ophthalmologists in 
the belief that an ocular abnormality is causing their 
visual symptoms, sometimes leading to unnecessary 
medical procedures such as cataract surgery.
The symptoms reported by a patient with PCA probably 
indicate broadly their individual pattern of neuropsycho-
logical impairment. Visual symptoms are perhaps more 
likely to be mentioned than other posterior deﬁ cits, with 
individuals describing diﬃ  culties reading lines of text, 
judging distances (often leading to repeat minor car 
accidents or diﬃ  culties parking), identifying static objects 
within the visual ﬁ eld, or having problems with stairs 
and escalators (panel). Visual symptoms such as light 
sensitivity or visual distortions can be mistaken for 
migraine. Careful history taking could reveal some of the 
more unusual visual phenomena described above, 
including the presence of prolonged after-images or 
visual crowding. Individuals might volunteer diﬃ  culties 
in using common objects, suggesting dyspraxia, or 
describe progressive diﬃ  culty with calculations or 
spelling. The presence of other neurological symptoms, 
including visual hallucinations (reported in up to 25% of 
patients with PCA)19,21,43 and rapid eye movement (REM) 
sleep behaviour disorder, could be suggestive of 
underlying dementia with Lewy bodies. Very occasionally, 
the patient’s history might be consistent with occipital 
lobe seizures.
Careful bedside testing can elicit signs of dispro-
portionate parietal or occipital dysfunction, including 
(but not restricted to) visual disorientation, diﬃ  culties 
resolving degraded stimuli, ideational or ideomotor 
dyspraxia (or both), dyscalculia, and problems with 
spelling (ﬁ gure 2A). The physical examination in most 
cases of PCA is unremarkable; however, if severe cortical 
visual impairments are present, interpretation of visual 
acuity and visual ﬁ elds can be diﬃ  cult, with hemianopia 
sometimes misdiagnosed owing to the presence of 
higher-order visual attentional impairments. Finger 
myoclonus is also not uncommon. Snowden and 
colleagues18 reported similar frequencies of extra-
pyramidal signs (41%), myoclonus (24%), and grasp 
reﬂ ex (26%) in individuals with PCA compared with 
those seen in patients with typical Alzheimer’s disease. 
Nonetheless, features of clear symmetrical motor 
parkinsonism (suggestive of Lewy body pathology) or 
prominent asymmetric myoclonus and dystonia 
(suggestive of corticobasal degeneration) can give 
important clues to the underlying cause of PCA, although 
pathological data on which these clinical observations 
can be conﬁ rmed are currently sparse.
Neuroimaging
Increasingly advanced image analysis techniques have 
been used to localise and quantify (typically group) 
diﬀ erences in patterns of atrophy in patients with PCA, 
compared either with controls or with patients with 
typical Alzheimer’s disease. Cross-sectional voxel-based 
morphometry has shown widespread diﬀ erences in grey 
matter between patients with PCA and healthy controls, 
with the most signiﬁ cant reductions found in regions of 
the occipital and parietal lobes followed by areas in the 
Panel: Case study
A 62-year-old right-handed woman presented with 4 years of progressive visuospatial 
dysfunction. Her ﬁ rst symptom was diﬃ  culty seeing when driving at night. In the 
following years she frequently dented her car when parking, tended to bump into doors 
on her right side, and had trouble locating items even when they were directly in front of 
her. She reported problems reading, trouble distinguishing between currency bank notes, 
and diﬃ  culty deciding whether to push or pull a door to open it. When she watched 
television, images seemed to move slowly. She was referred to the cognitive neurology 
clinic by an ophthalmologist, who had ruled out primary ocular disease. On neurological 
assessment she was fully oriented and was an excellent historian. On testing of visual 
ﬁ elds, she was inconsistent in counting ﬁ ngers in the right hemiﬁ eld. Pupillary responses 
and extraocular movements were normal, although she was slow initiating saccades and 
had diﬃ  culty reaching for items under visual guidance. Her physical neurological 
examination was otherwise normal. On cognitive testing, her MMSE score was 26/30, and 
she showed severe impairment when copying intersecting pentagons and the Benson 
ﬁ gure (ﬁ gure 2A). She was able to name colours correctly but showed moderate diﬃ  culty 
matching faces. She had severe diﬃ  culty reading, which was improved by spelling words 
out loud, and had mild deﬁ cits in confrontation naming (improved with cues) and 
category ﬂ uency. Verbal memory, phonemic ﬂ uency, and attention were intact. She could 
not complete many tasks because of visual dysfunction. Brain MRI showed striking 
atrophy in bilateral parietal, posterior temporal, and lateral occipital cortex 
(ﬁ gure 2B [upper row]), and ﬂ uorodeoxyglucose (FDG)-PET (ﬁ gure 2B [middle row]) 
showed hypometabolism in the same regions, left worse than right. Frontal cortex, 
medial temporal cortex, and hippocampus were spared. Pittsburgh compound (PiB)-PET 
showed diﬀ use cortical uptake throughout posterior and anterior cortical regions alike 
(ﬁ gure 2B [lower row]), consistent with underlying amyloid-β plaques.
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temporal lobe.24,30 Direct comparison between individuals 
with PCA and typical Alzheimer’s disease, using 
both voxel-based morphometry and cortical thickness 
measures, has shown greater right parietal and less left 
medial temporal and hippocampal atrophy in patients 
with PCA. It is noteworthy that in several studies, 
researchers report asymmetric atrophy patterns in PCA 
(right greater than left), but these diﬀ erences could be 
due to selection biases in the diagnosis and recruitment 
of patients with prominent visual dysfunction. Limited 
data from diﬀ usion tensor imaging studies also suggest 
that PCA reduces the integrity of white matter tracts 
in posterior brain regions.44–46 However, considerable 
regional overlap in atrophy has also been reported, with 
regions including the posterior cingulate gyri, precuneus, 
and inferior parietal lobe being aﬀ ected in both PCA and 
typical Alzheimer’s disease.23 Such ﬁ ndings suggest that 
PCA, when associated with Alzheimer’s disease, exists 
on a spectrum of variation with other phenotypes of 
Alzheimer’s disease.23,32 Fluid registration of longitu-
dinally acquired structural magnetic resonance (MR) 
images shows the evolution of PCA (ﬁ gure 3), with 
ﬁ ndings of group studies indicating that, by 5 years of 
symptom duration, atrophy is widespread throughout 
the cortex, including medial temporal lobe structures.31
Data from functional imaging studies using single 
photon emission computed tomography (SPECT) 
and ﬂ uorodeoxyglucose (FDG) PET accord largely 
with structural changes in parieto-occipital areas 
(ﬁ gure 2B).20,47–51 In addition to posterior regions, 
FDG-PET has indicated speciﬁ c areas of hypometabolism 
in the frontal eye ﬁ elds bilaterally, which can occur 
secondary to loss of input from occipitoparietal regions 
and be the cause of oculomotor apraxia in PCA 
(ﬁ gure 1).20,52 In a few studies, researchers have also 
assessed patterns of amyloid deposition with Pittsburgh 
compound B (PiB)-PET in patients with PCA. Case 
studies and small series have shown increased 
accumulation of amyloid-β, predominantly in the 
occipital and parietal lobes, relative to individuals with 
typical Alzheimer’s disease.53–56 However, in two studies 
in which PiB uptake was compared in large groups of 
patients with PCA and typical Alzheimer’s disease, no 
signiﬁ cant diﬀ erence was reported in amyloid deposition 
between these groups, with both showing diﬀ use PiB 
uptake through out frontal, temporoparietal, and occipital 
cortex (ﬁ gure 2B).22,57
Genetics
To date, no reports have been published of a PCA 
phenotype associated with autosomal dominant familial 
Alzheimer’s disease; however, in a case series,58 the 
PCA syndrome was described in familial prion disease 
associated with a 5-octapeptide insertion into the prion 
protein. Findings from available PCA case series 
suggest that there is no signiﬁ cant diﬀ erence in the 
number of patients with a positive family history of 
dementia in PCA and with typical Alzheimer’s 
disease.17,21 In some studies, signiﬁ cant diﬀ erences 
between apolipoprotein E (APOE) genotypes have been 
noted in patients with PCA versus amnestic Alzheimer’s 
disease.14,18,59 However, in other studies, no diﬀ erence in 
APOE was recorded between PCA and typical 
Alzheimer’s disease (table).17,21–23,60–64 Discrepancies 
between these studies could be attributable to 
diﬀ erences in the inclusion criteria used to deﬁ ne PCA 
and typical Alzheimer’s disease and age at onset. In 
particular, scant pathological conﬁ rmation is a major 
limitation of these studies.
Does the APOE ε4 allele drive the degenerative pattern 
in patients with Alzheimer’s disease (ie, to or away from 
medial temporal structures)? Is the low frequency of 
APOE ε4 in PCA that is reported in some studies 
attributable to patients with non-Alzheimer’s disease 
Figure 2: Neuropsychological and neuroimaging evidence of posterior cortical atrophy
Neurological testing (A) and brain imaging (B) of a 62-year-old woman with visuospatial dysfunction. Images are 
in neurological orientation. See the panel for a description of the case history and imaging ﬁ ndings.
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pathology? Do diﬀ erent (as yet unrecognised) genetic 
factors underlie PCA compared with so-called typical 
late-onset Alzheimer’s disease? Studies with large sample 
sizes, consistent deﬁ nitions of PCA, and post-mortem 
conﬁ rmation of diagnosis are needed to obtain conclusive 
results. Genome-wide association studies to assess 
frequencies of other genetic risk factors for sporadic 
Alzheimer’s disease will be useful.
Pathology
Findings of pathological studies all show that Alzheimer’s 
disease is the most common underlying cause of 
PCA.13,15,21,65–67 However, some cases are attributable to 
other causes, such as corticobasal degeneration,15,68,69 
dementia with Lewy bodies,15,70 prion disease (including 
CJD and familial fatal insomnia),15,71 and subcortical 
gliosis.71 In the largest series studied to date, Renner and 
colleagues15 reported pathological data for 21 patients 
with PCA, of whom 13 had Alzheimer’s disease, two had 
pathological features of an Alzheimer’s disease-Lewy 
body variant, one had Alzheimer’s disease with coexisting 
Parkinson’s disease, one had dementia with Lewy bodies 
with coexisting subcortical gliosis, two had corticobasal 
degeneration, and two had prion disease (CJD and fatal 
familial insomnia). Tang-Wai and colleagues21 reported 
that seven of nine patients with PCA had pathological 
features of Alzheimer’s disease, whereas the other two 
had corticobasal degeneration.21
Although the distribution patterns of pathological 
features diﬀ er between PCA and typical Alzheimer’s 
disease, the exact pattern of pathological changes is 
inconsistent and based on very few cases. Some studies 
have shown diﬀ erences in both plaques and neuro-
ﬁ brillary tangles between PCA and typical Alzheimer’s 
disease,10,12,72 whereas others have recorded no diﬀ erences 
in plaque distribution.15,21 For example, Levine and 
colleagues10 reported pathological ﬁ ndings of one 
patient with PCA who showed the greatest density of 
senile plaques and neuroﬁ brillary tangles in occipito-
parietal regions and the lowest density in frontal lobe 
regions. Hof and co-workers72,73 reported similar 
ﬁ ndings, with plaques and tangles found predominantly 
in primary visual and visual association areas around 
the occipitoparietotemporal junction, whereas frontal 
regions—such as the prefrontal cortex—had very low 
densities of pathological changes. By contrast, Tang-Wai 
and colleagues21 looked at pathological changes in nine 
patients with PCA versus 30 with typical Alzheimer’s 
disease. The PCA group showed signiﬁ cantly higher 
densities of neuroﬁ brillary tangles in visual and visual-
association cortices and fewer tangles and senile 
plaques in the hippocampus and subiculum. However, 
density of senile plaques in other cortical areas was 
comparable in both groups.21 Reasons for the discrepant 
ﬁ ndings in these autopsy studies could include 
diﬀ erences in inclusion criteria and demographic 
characteristics (such as age and disease severity) and 
diﬀ erences in the methods used to quantify pathological 
changes (such as diﬀ erent staining techniques and 
discrimination between diﬀ use and neuritic plaques). 
Studies in which CSF biomarkers (Aβ1–42, T-tau, and 
P-tau181) were assessed have recorded similar ﬁ ndings 
in patients with PCA compared with Alzheimer’s 
disease,27,56,60,74 lending support to previous reports that 
PCA is associated typically with underlying Alzheimer’s 
disease pathology.
Diagnostic and research criteria
Two sets of diagnostic criteria for PCA have been 
proposed.17,21 Suggested core features for a diagnosis of 
PCA include insidious onset and gradual progression; 
presentation of visual deﬁ cits in the absence of ocular 
disease; relatively preserved episodic memory, verbal 
ﬂ uency, and personal insight; presence of symptoms 
including visual agnosia, simultanagnosia, optic ataxia, 
ocular apraxia, dyspraxia and environmental disorien-
tation; and absence of stroke or tumour. Supportive 
features include alexia, ideomotor apraxia, agraphia, 
acalculia, onset before the age of 65 years, and 
neuroimaging evidence of PCA or hypoperfusion.
Although these criteria have proved useful in several 
clinical and research contexts, they are based on clinical 
experience at single centres and have not been validated 
more widely. Without objective evidence linking clinical 
phenotype to underlying pathology, there continues to 
be inconsistency, with the term PCA being used as a 
descriptive syndromic term and as a diagnostic label. 
Such inconsistencies present several diﬃ  culties in 
Figure 3: Evolution of neurodegeneration in posterior cortical atrophy
Registered serial MRIs showing axial views of a woman with posterior cortical atrophy at four timepoints 
(age 59–63 years old). Repeat scans were ﬂ uid-registered to the baseline image and colour-coded 
voxel-compression maps were produced. The scale shows the percentage volume change per voxel (–20 to 20%), 
with green and blue representing contraction and yellow and red representing expansion.
Repeat 1: October 2006
Structural MRI (T1)
Fluid maps
Repeat 2: November 2007 Repeat 3: October 2008Baseline: October 2005
L
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attributing and assessing the validity of a diagnosis of 
PCA and, particularly, in the design and interpretation of 
research studies and clinical trials. First, although a 
syndromic classiﬁ cation could be adequate for some 
types of research study (eg, brain–behaviour, behavioural 
intervention), other investigations will need direct 
consideration of probable underlying pathological 
features (eg, clinical trials of disease-speciﬁ c drugs). 
Second, at present, we have no evidence base on which to 
judge the eﬀ ectiveness of pharmacological treatments 
for Alzheimer’s disease in individuals with PCA 
attributable to probable Alzheimer’s disease or to decide 
whether individuals with PCA should be included or 
excluded from conventional clinical trials of Alzheimer’s 
disease—eg, because of the potential unsuitability of 
study outcome measures (eg, visual memory tasks) 
selected for patients with more typical amnestic or global 
clinical presentations. Third, current criteria provide no 
guidance about the degree of speciﬁ city needed for a 
diagnosis of PCA. For example, in the relatively large 
series reported by Renner and colleagues,15 nine of 
27 patients presented with PCA as a fairly isolated 
disorder, whereas in the remaining 18 people it was the 
prominent feature of a more generalised dementia. 
Several groups have suggested that PCA, when 
attributable to probable Alzheimer’s disease, lies on a 
phenotypic continuum with other typical and atypical 
Alzheimer’s phenotypes (eg, amnestic Alzheimer’s 
disease, global cognitive impairment, logopenic or 
phonological aphasia),18,23,32 but the boundaries between 
such phenotypes are deﬁ ned imprecisely. Fourth, the 
presentation of visual complaints is a core feature of 
existing criteria but some patients with neurodegenerative 
disorders present with predominant impairment of other 
posterior cortical functions, such as calculation, spelling, 
and praxis;6,18,27,48,75 such individuals could be deemed to 
fall within the PCA spectrum. Finally, the value of 
biomarkers might diﬀ er in PCA compared with typical 
Alzheimer’s disease or dementia with Lewy bodies 
(eg, relative absence of hippocampal atrophy). This issue 
is especially important in view of the increasing 
incorporation of such biomarkers in disease-speciﬁ c 
diagnostic criteria.76,77
Future resolution of these issues and development of 
clinical and research criteria for the deﬁ nition of PCA are 
likely to be based on a consensus of opinion from many 
specialist centres, supported by objective evidence of the 
relation between clinical presentation, neuroimaging and 
CSF biomarkers, and histopathological data. Establish-
ment of the relative likelihood of diﬀ erent pathologies in 
large, multicentre datasets would improve the discrim i-
nation of potential disease subtypes necessary for trials of 
disease-modifying agents. One possible approach would 
be to apply a range of criteria to a multicentre dataset to 
establish sets of inclusion and exclusion criteria that 
identify speciﬁ c disease subgroups (eg, PCA with 
Alzheimer’s disease). By consensus, experts could also 
investigate frameworks for making criteria useable, in 
terms of a quantiﬁ able set of diagnostic markers, to help 
with enrolment into research studies and to improve the 
comparability of data between institutions.
Management
As far as we know, no reports have been published that 
assess the eﬀ ectiveness of acetylcholinesterase inhibitors 
(eg, donepezil, rivastigmine, and galantamine) in PCA. 
However, these drugs are frequently and, in our view 
(since Alzheimer’s disease is the most likely underlying 
pathology), appropriately administered. Clinical experi-
ence and a few case reports suggest some clinical 
beneﬁ t,78 most probably in patients with underlying 
pathological features of Alzheimer’s disease or dementia 
with Lewy bodies. Antidepressant drugs might also be 
appropriate in patients with persistent low mood, and 
trials of levodopa or carbidopa could be useful in 
individuals with parkinsonism.
Posterior cortical atrophy Alzheimer’s disease Controls
Total 
(n)
Age at 
onset 
(years)*
APOE 
(n)
ε4 
frequency 
(%)
ε4-
positive 
(%)
Total 
(n)
Age at 
onset 
(years)*
APOE 
(n)
ε4 
frequency 
(%)
ε4-
positive 
(%)
Total 
(n)
ε4 
frequency 
(%)
ε4-
positive 
(%)
Mendez (2002)17 15 58·2 (5·1) 8 25 50 176† ·· 176 40 ·· ·· ·· ··
Tang-Wai (2004)21 40 60·5 (8·9) 27 26 48 5107‡ ·· 5107 37 59 6262‡ 14 26
Schott (2006)14§ 10 56·1 (4·1) 10 10 20 29 65·6 (6·9) 29 52 86 ·· ·· ··
Snowden (2007)18§ 24 58·0 (4·0) ·· ·· 30 321 58·0 (4·0) ·· ·· 82¶ 767|| 14 27
Migliaccio (2009)23 14 ·· 11 ·· 55 16 ·· 9 ·· 56 44 ·· 23
Baumann (2010)60 9 56·7 (7·6) 9 ·· 39 11 58·3 (5·1) 11 ·· 50 14 ·· 14
Rosenbloom (2011)22 12 57·5 (7·4) 9 33 44 14 58·8 (9·6) 11 59 73 ·· ·· ··
Data are from seven studies that have reported APOE ε4 frequency in posterior cortical atrophy, typical (or sporadic) Alzheimer’s disease, and healthy controls. *For whole 
groups of patients with posterior cortical atrophy and Alzheimer’s disease, the age at onset for the subsample of patients with APOE ε4 was unknown, except for Schott14 and 
Baumann.60 †Saunders (1993).61 ‡Farrer (1997).62 §Reported signiﬁ cant diﬀ erence in APOE ε4 between patients with posterior cortical atrophy and Alzheimer’s disease. 
¶Amnestic Alzheimer’s disease; 80% were ε4-positive in the memory and semantic Alzheimer’s disease group. ||Pendleton (2002).64
Table: Prevalence of the APOE ε4 allele in posterior cortical atrophy and Alzheimer’s disease
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Because of poor awareness of PCA, patients with this 
disorder typically receive scant or inappropriate care and 
advice, whereby diﬃ  culties that are less important to the 
individual (eg, memory problems) are targeted while vital 
perceptual diﬃ  culties (eg, many activities in day centres 
and nursing homes are visually mediated) are, in general, 
not considered. Preservation of skills such as memory, 
language, and insight in PCA, especially in mild-to-
moderate stages of the disease, enables patients to take 
advantage of peer-support meetings and group, couple, 
and individual psychological treatments when the need 
exists. Support group meetings are especially useful in 
tackling social isolation, allowing patients to share the 
experience of what is often a long and diﬃ  cult route to 
diagnosis, and to exchange practical tips and coping 
strategies and advice. Patients with PCA often beneﬁ t 
from resources designed primarily for blind and partially 
sighted people, such as mobile phones with simpliﬁ ed 
displays, voice recognition software, talking books and 
watches, culinary aids, and lamps to increase ambient 
light levels in the home. Referral to an occupational 
therapist or sensory team could be appropriate to help a 
patient participate more fully in activities of daily living. 
An individual might also need to be referred to an 
ophthalmologist to register as partially sighted under 
statutory invalidity schemes, which might then provide 
access to ﬁ nancial and social beneﬁ ts and services. 
Driving a car is not appropriate for many people with 
PCA, particularly those with prominent visual disturbance. 
Physical therapy can also be helpful for individuals with 
parkinsonism and gait disturbance. Scant empirical 
evidence shows the eﬀ ect of management strategies in 
PCA, but a rehabilitation programme that included 
psychoeducation, compensatory strategies, and cognitive 
exercises was tested in an individual with PCA,79 resulting 
in small improvements in visuo perceptual functioning.
Conclusions
Posterior cortical atrophy is a debilitating and under-
recognised focal degenerative syndrome that is associated 
with a range of diﬀ erent disease pathologies. The core 
features of the syndrome are suﬃ  ciently homogeneous 
to justify regarding PCA as an independent nosology, 
with Alzheimer’s disease as the most common 
underlying cause. However a lack of consistency in the 
classiﬁ cation of PCA is likely to continue unless 
diagnostic criteria and terminology are standardised. 
The criteria proposed in this Review attempt to take both 
the clinical and histo pathological features of PCA into 
account and to introduce quantiﬁ able behavioural 
inclusion criteria for research studies of PCA. Better 
understanding and aware ness of the syndrome by 
medical and lay workers is necessary to improve 
diagnosis and treatment and to enhance support services 
for individuals with PCA and their families. Identiﬁ cation 
of the distinctive patterns of struc tural, functional, 
cognitive, and genetic changes in PCA could provide 
new insights into the pathogenesis and clinical features 
of typical Alzheimer’s disease and into general 
mechanisms of visual network function and degeneration. 
Dedicated trials are needed to assess the eﬀ ectiveness of 
pharmacological and non-pharmacological interventions 
in PCA, and to identify factors that drive phenotypic 
variability in this small but important population of 
patients who typically have early-onset dementia.
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